Healthcare & Health Industry Wire — Week of June 30, 2026

A $120 million voice artificial intelligence (AI) round, two oncology approvals, and a dialysis payment proposal made this a week where operational automation and chronic-disease infrastructure mattered more than splashy consumer health launches.

Assort Health raised $120 million in Series C funding led by Menlo Ventures and reached a $1.2 billion valuation, according to Fierce Healthcare's June 24 report. The company has now raised $222 million since launching in November 2023. 1

The useful detail is not only the valuation. Assort is pitching specialty-specific voice AI agents that handle appointment scheduling, intake, referrals, document processing, medication refills, real-time insurance eligibility, lab requests, and payments. Fierce reported that the company says its model is trained on 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways. 1

For providers, the commercial promise is front-office capacity without hiring at the same pace. For patients, the risk is different: if an AI agent becomes the first point of contact, the handoff from automated intake to a clinician has to be clear when symptoms are urgent, complex, or emotionally sensitive. Assort says customers can see a 5% lift in appointment volume and a 115% increase in labor capacity, but those figures come from the company rather than an independent outcomes study. 1

The U.S. Food and Drug Administration (FDA) cleared two oncology expansions on June 24, both in breast cancer, and separately warned device sponsors that unreliable third-party testing data can stop a device submission from being authorized.

The oncology approvals are clinically specific rather than broad platform news. The palbociclib label depends on tumor receptor status and prior induction treatment, while the sacituzumab approval splits patients by whether they are candidates for PD-1 or PD-L1 inhibitor therapy. Those details matter for patients reading headlines: neither approval means a universal first-line breast-cancer option.

The Centers for Medicare & Medicaid Services (CMS) proposed updates to the end-stage renal disease (ESRD) Prospective Payment System (PPS) for dialysis services furnished to Medicare beneficiaries on or after January 1, 2027. CMS said the proposed $299.55 base rate would raise total payments to all ESRD facilities by about 1.1% compared with 2026. 5

The proposal folds phosphate binders into the bundled dialysis payment, adding $15.96 to the base rate, and would raise the home and self-dialysis training add-on from $95.60 to $138.22. CMS also proposed allowing that training add-on during the first four months of dialysis, a period when the current ESRD PPS does not pay it. 5

For clinics, the low-volume payment adjustment proposal is the part to model. CMS would raise the threshold from 4,000 to 8,000 treatments and expand the adjustment from two tiers to six, while reducing the base rate by about 1.1% to keep the change budget-neutral. 5

For patients, the home-dialysis language is the practical signal. If finalized, the rule would put more Medicare dollars behind training patients and caregivers to perform dialysis at home, but it would not automatically make home dialysis right for every patient. Eligibility still depends on clinical condition, home support, training capacity, and shared decision-making with a nephrology team.

The University of Arkansas Board of Trustees approved a University of Arkansas for Medical Sciences (UAMS) plan to lease and operate Encore Medical Center in Bryant, a 53-licensed-bed, 108,055-square-foot acute-care hospital. UAMS said the facility will become the newest hospital in the UAMS Health system and extend its clinical footprint into Saline County. 6

The transaction is structured as a lease rather than a straightforward purchase by UAMS. UAMS said The Landes Group, a Dallas-based real estate investment firm, is expected to acquire the property from Arkansas Heart Hospital by late summer; UAMS then expects to finalize the lease in the coming weeks and assume full operational authority on October 1, 2026. 6

The rationale is capacity. UAMS Chancellor C. Lowry Barnes said the additional 53 beds would help UAMS accept more transfers of critically ill patients from other Arkansas hospitals, and the release said Saline County's population has grown 25% since 2010, adding more than 27,000 residents. 6

This is the kind of hospital transaction that may matter locally before it matters nationally. It changes capacity, transfer options, and specialty access in central Arkansas without the headline dollar figure of a large system merger.

This week's CMS dialysis proposal is about payment mechanics, but it points to a patient-facing issue: kidney disease is often silent until late stages. The Centers for Disease Control and Prevention (CDC) says more than 1 in 7 U.S. adults has chronic kidney disease (CKD), and as many as 9 in 10 do not know they have it. 7

If you have diabetes, high blood pressure, heart disease, or a family history of kidney failure, ask your clinician whether you are due for two kidney checks: a blood test for estimated glomerular filtration rate (eGFR), which estimates how well the kidneys filter blood, and a urine albumin test, often reported as a urine albumin-to-creatinine ratio (UACR). The National Institute of Diabetes and Digestive and Kidney Diseases says people with diabetes should be checked every year; people with high blood pressure, heart disease, or a family history of kidney failure should ask how often they need testing. 8

A normal UACR is 30 mg/g or less; a result above 30 mg/g may be a sign of kidney disease and usually needs follow-up rather than one-off panic. NIDDK says clinicians may repeat the urine test one or two more times to confirm albumin in the urine. 8

Bring the exact numbers to your next visit. Ask: "What is my eGFR? What is my UACR? Do either change my blood pressure, diabetes, or medication plan?" That three-question script turns kidney screening from a lab result buried in the portal into a prevention conversation.